2025 is surging with breakthrough progress to combat CNS disorders given the rapidly increasing unmet need, with payers evidently showing greater receptiveness to innovation. However, with access limited by the extreme costs of novel disease-modifying therapies, a growing competition with generics, and the movement towards precision neuroscience introducing challenges of patient finding, it is crucial for drug developers to consider market access earlier on and strategize how to better demonstrate value over the current standard of care.

Uniquely positioned to address the commercial challenges specific to this niche space, the 2025 Market Access for CNS Therapeutics Summit fulfilled the strong demand for a forum dedicated to promoting earlier commercial conversations to succeed in establishing new therapies for neurodegeneration, mental health, neuromuscular disorders, and more.